The UK pharmaceuticals giant GlaxoSmithKline (GSK) said Monday it was joining a global race to develop a vaccine for a new strain of a deadly coronavirus that has killed more than 360 people.
The UK government also pledged £20 million ($26 million, 24 million euros) in funding for research at the Coalition for Epidemic Preparedness Innovations (CEPI)—a civil group formed at the World Economic Forum in Davos in 2017.
GSK said its work will complement the four projects already being funded through CEPI to develop a vaccine for the deadly China strain.
“Our (vaccine) adjuvant technology has previously been used successfully in the pandemic flu setting,” GSK Vaccine chief medical officer Thomas Breuer said in a statement.
“It enables using only small quantities of the vaccine antigen which allows the production of more doses of the vaccine—a crucial advantage in a pandemic.”
Adjuvant are agents that boost a body’s response to vaccine or other treatment.
The World Health Organization has declared a global virus emergency but refrained from calling the new epidemic a “pandemic”.
That term is reserved for disease that spread across multiple continents or worldwide.
CEPI was originally formed in response to the Ebola epidemic that killed more than 11,300 people of the 29,000 recorded cases in west Africa from 2013 to 2016.
“Our hope is that, with our partners, we can get an investigational vaccine from gene sequencing of the pathogen through to clinical testing in 16 week,” CEPI chief executive Richard Hatchett said.
CEPI’s four other projects aimed at stamping out the new strain include a partnership between the US biotech company Moderna and the US National Institute of Allergy and Infectious Diseases.
GSK said it will initially be joining the work already being performed by the University of Queensland in Australia.
The other two projects involve the German biopharmaceutical company CureVac and the US-based Inovio pharmaceuticals firm.
Source: Read Full Article